Skip to main content

Amphastar Pharmaceuticals Inc. Value Stock - Dividend - Research Selection

Amphastar pharmaceutical

ISIN: US03209R1032 , WKN: A11664

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies London Healthcare Conference 2025 - Slideshow

2025-11-19
2025-11-19. The following slide deck was published by Amphastar Pharmaceuticals, Inc.

IHF: Healthcare Dashboard For November

2025-11-19
Healthcare providers are undervalued. Click here to find out which stocks are the cheapest and if the IHF ETF is a risky buy.

3 Small-Cap Stocks with Questionable Fundamentals

2025-11-18
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Why Amphastar Pharmaceuticals (AMPH) Is Up 8.4% After Strong Q3 Revenue and Key FDA Approvals

2025-11-15
Amphastar Pharmaceuticals reported its third-quarter 2025 results, revealing quarterly revenues of US$191.84 million and net income of US$17.35 million, with sales of Baqsimi and Primatene Mist contributing to performance and recent pipeline and product expansion announced. Despite a dip in profits from the previous year, the company secured key FDA product approvals, entered new licensing agreements, and saw continued growth in its two primary products, indicating active efforts to...

5 Must-Read Analyst Questions From Amphastar Pharmaceuticals’s Q3 Earnings Call

2025-11-13
Amphastar Pharmaceuticals' third quarter results for 2025 came in ahead of Wall Street's revenue and profit expectations, despite essentially flat sales compared to the prior year. The quarter was shaped by strong performances from proprietary products BAQSIMI and Primatene MIST, both of which saw double-digit sales growth. Management attributed this momentum to enhanced commercial execution and expanded marketing partnerships. At the same time, the company faced pronounced margin pressure, prim

Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today

2025-11-12
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial results for the third quarter of 2025, showing resilient performance and robust sales growth. In its earnings report from the previous day, the company disclosed net revenues of $191.8 million for the quarter. Furthermore, its adjusted net income reached $44.7 million, which translated to $0.93 per

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

2025-11-12
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated ...

Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best

2025-11-12
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today

2025-11-10
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.9% in the afternoon session after the stock's positive momentum continued as the company reported third-quarter financial results that surpassed analyst expectations. Amphastar posted revenue of $191.8 million and adjusted earnings of $0.93 per share, beating Wall Street's consensus estimates. The strong performance was reportedly driven by robust sales of its products Baqsimi and Primatene Mist. Following the resu

AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures

2025-11-10
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $191.8 million. Its non-GAAP profit of $0.93 per share was 12.7% above analysts’ consensus estimates.